P-糖蛋白和肺耐药蛋白在浸润性乳腺癌中的表达及其临床意义

目的探讨P-糖蛋白(P-gp)和肺耐药蛋白(LRP)在浸润性乳腺癌中的表达情况及其临床意义。方法采用搓网法获取乳腺癌手术切除标本制成的完整单细胞悬液,再用流式细胞技术对40例乳腺癌组织及相应癌旁组织中P-gp、LRP的表达情况进行定量分析。结果乳腺癌组织P-gp、LRP表达与相应癌旁组织比较,差异均有统计学意义(P-gp:t=-7.777,LRP:t=-9.861,P均0.050)。在不同年龄、肿瘤大小、病理类型、临床分期、分化程度和雌、孕激素受体状态的患者间,两种耐药相关蛋白的表达差异均无统计学意义(P0.050)。有淋巴结转移组P-gp表达与无淋巴结转移组比较,差异无统计学意义(t=0.102,P=0.919)。有淋巴结转移组LRP的表达为(41.2±18.5)%,无淋巴结转移组为(30.1±15.4)%,有淋巴结转移组LRP表达显著高于无淋巴结转移组(t=2.074,P=0.045)。乳腺癌组织P-gp与LRP的表达间存在正相关性(r=0.698,P0.001)。结论本研究结果可为寻找浸润性乳腺癌的有效辅助化疗药物提供参考。

Expressions of P-glycoprotein and lung resistance protein in invasive breast carcinoma tissues and clinical significance

Objective To investigate the expressions of P-glycoprotein（P-gp） and lung resistance protein（LRP）in breast carcinoma tissues and their clinical significance.Methods Single-cell suspension with intact cellular membrane taken from breast cancer resection specimens were prepared using rubbing-net technique and flow cytometry（FCM）was used to quantitatively examine the expressions of P-gp and LRP in carcinoma tissues and corresponding peri-carcinoma tissues in 40breast cancer cases.Results The expressions of P-gp and LRP in breast cancer tissues were statistically different from those of the corresponding peri-carcer tissues（P〈0.050）.No statistically significant difference existed in the P-gp and LRP expressions of the tumor cells in age,tumor size,pathological types,clinical stages and cell differentiation degree,and between negative and positive expressions of the estrogen and progestin receptors of the patients（P〉0.05）.There was no statistical difference in P-gp expression between the lymph node metastasis negative and positive patients（t=0.102,P=0.919）.The expression of LRP was higher in the lymph node metastasis patients（41.2±18.5）%than that in the non-metastasis patients（30.1± 15.4）%（t=2.074,P=0.045）.There was a positive correlation between the expression of P-gp and the expression of LRP（r=0.698,P〈0.001）.Conclusions The results of this study provides references in looking for effective chemotherapy drugs for invasive breast cancer.